NCT04862286: Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
- State
- Under way
- Phase
- Phase 3
- People
- 132 planned
- Started
- 24 Jul 2021
- Primary completion
- Apr 2028
- Arms
- Risankizumab
- Results
- None posted
- 27 Apr 2021: Trial registered
- 24 Jul 2021: Trial started